AR079128A1 - Procedimiento para preparar un polimorfo de la sal de colina de (4,6-bis( dimetilamino)2-(4-((4-(trifluorometil)-benzoil) amino) bencil) pirimidin-5-ilo - Google Patents

Procedimiento para preparar un polimorfo de la sal de colina de (4,6-bis( dimetilamino)2-(4-((4-(trifluorometil)-benzoil) amino) bencil) pirimidin-5-ilo

Info

Publication number
AR079128A1
AR079128A1 ARP100104319A ARP100104319A AR079128A1 AR 079128 A1 AR079128 A1 AR 079128A1 AR P100104319 A ARP100104319 A AR P100104319A AR P100104319 A ARP100104319 A AR P100104319A AR 079128 A1 AR079128 A1 AR 079128A1
Authority
AR
Argentina
Prior art keywords
salt
trifluorometil
bencil
pirimidin
benzoil
Prior art date
Application number
ARP100104319A
Other languages
English (en)
Inventor
Xiao-Jun Wang
Bing-Shiou Yang
Dhileep Kumar Krishnamurthy
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43447007&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR079128(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of AR079128A1 publication Critical patent/AR079128A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/48—Two nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Composiciones farmacéuticas. Reivindicacion 1: Un procedimiento caracterizado porque es para preparar una forma cristalina de la sal de colina del compuesto de formula (1), comprendiendo el procedimiento: (a) formar una primera mezcla de una sal de colina del compuesto de formula (1) en un disolvente que comprende isopropanol y agua; (b) poner en contacto la primera mezcla de la Etapa (a) con un antidisolvente para proporcionar una segunda mezcla; y (c) dejar que la sal de colina del compuesto de formula (1) cristalice a partir de dicha segunda mezcla de la Etapa (b) para proporcionar la forma cristalina del compuesto de formula (1).
ARP100104319A 2009-11-24 2010-11-23 Procedimiento para preparar un polimorfo de la sal de colina de (4,6-bis( dimetilamino)2-(4-((4-(trifluorometil)-benzoil) amino) bencil) pirimidin-5-ilo AR079128A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US26387109P 2009-11-24 2009-11-24

Publications (1)

Publication Number Publication Date
AR079128A1 true AR079128A1 (es) 2011-12-28

Family

ID=43447007

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP100104319A AR079128A1 (es) 2009-11-24 2010-11-23 Procedimiento para preparar un polimorfo de la sal de colina de (4,6-bis( dimetilamino)2-(4-((4-(trifluorometil)-benzoil) amino) bencil) pirimidin-5-ilo

Country Status (15)

Country Link
US (1) US20110294828A1 (es)
EP (1) EP2504319A1 (es)
JP (1) JP2013512242A (es)
KR (1) KR20120101399A (es)
CN (1) CN102666499A (es)
AR (1) AR079128A1 (es)
AU (1) AU2010324980A1 (es)
BR (1) BR112012012384A2 (es)
CA (1) CA2781610A1 (es)
CL (1) CL2012001170A1 (es)
EA (1) EA201200765A1 (es)
IL (1) IL218990A0 (es)
MX (1) MX2012006003A (es)
TW (1) TW201200501A (es)
WO (1) WO2011066176A1 (es)

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4570630A (en) 1983-08-03 1986-02-18 Miles Laboratories, Inc. Medicament inhalation device
NO166268C (no) 1985-07-30 1991-07-03 Glaxo Group Ltd Innretning for administrering av medikamenter til pasienter.
SE453566B (sv) 1986-03-07 1988-02-15 Draco Ab Anordning vid pulverinhalatorer
SG45171A1 (en) 1990-03-21 1998-01-16 Boehringer Ingelheim Int Atomising devices and methods
DE4318455A1 (de) 1993-06-03 1994-12-08 Boehringer Ingelheim Kg Kapselhalterung
DE19536902A1 (de) 1995-10-04 1997-04-10 Boehringer Ingelheim Int Vorrichtung zur Hochdruckerzeugung in einem Fluid in Miniaturausführung
DE60303238T2 (de) * 2003-04-25 2006-09-14 Actimis Pharmaceuticals, Inc., La Jolla Pyrimidin-Essigsäure Derivate geeignet zur Behandlung von CRTH2-bedingten Krankheiten
EP2051943A4 (en) 2006-08-03 2011-03-23 Bromine Compounds Ltd METHOD, DEVICE AND SYSTEM FOR WATER TREATMENT
US8278310B2 (en) 2007-06-21 2012-10-02 Actimis Pharmaceuticals, Inc. Amine salts of a CRTH2 antagonist
JP2010530425A (ja) 2007-06-21 2010-09-09 アクチミス ファーマシューティカルズ インコーポレーテッド Ｃｒｔｈ２アンタゴニストの粒子

Also Published As

Publication number Publication date
KR20120101399A (ko) 2012-09-13
EP2504319A1 (en) 2012-10-03
AU2010324980A1 (en) 2012-05-03
WO2011066176A1 (en) 2011-06-03
CL2012001170A1 (es) 2012-10-12
BR112012012384A2 (pt) 2016-03-22
US20110294828A1 (en) 2011-12-01
MX2012006003A (es) 2012-06-19
JP2013512242A (ja) 2013-04-11
CA2781610A1 (en) 2011-06-03
CN102666499A (zh) 2012-09-12
IL218990A0 (en) 2012-06-28
TW201200501A (en) 2012-01-01
EA201200765A1 (ru) 2013-02-28

Similar Documents

Publication Publication Date Title
CY1124874T1 (el) Διεργασια για την παρασκευη [(5-(3-χλωροφαινυλ)-3-υδροξυπυριδινο-2-καρβονυλ)-αμινο]οξικου οξεος απο 5-((3-χλωροφαινυλ)-3-χλωρο-πυριδιν-2-υλ)-νιτριλιο, και διεργασια για την παρασκευη παραγωγων 5-((αλογονοφαινυλ)-3-αλογονο-πυριδιν-2-υλ)-νιτριλιου
CR20140301A (es) Derivados de betulina
AR085155A1 (es) Procesos para preparar compuestos de quinolina y composiciones farmaceuticas que contienen dichos compuestos
ECSP11011398A (es) Inhibidores de beta-secretasa
EA201490569A1 (ru) Полиморфная форма гидрохлорида придопидина
UY33317A (es) Nuevos derivados de pirazol
CO6680645A2 (es) Inhibidores de oxadiazol de la producción de leucotrieno
PH12015501752B1 (en) Substituted bisphenyl butanoic phosphonic acid derivatives as nep inhibitors
CU20120137A7 (es) Hidrato del hidrocloruro de agomelatina y preparación de éste
EA201101147A1 (ru) Новый способ синтеза ивабрадина и его солей присоединения с фармацевтически приемлемой кислотой
CL2011001405A1 (es) Procedimiento para la preparacion de n-[2-(7-metoxi-1-naftil)etil]acetamida, agometalina.
CO6361993A2 (es) Compuestos de 4-[2-(2-fluorofenoximetil)fenil]piperidina
EA201000398A1 (ru) Новый способ синтеза ивабрадина и его солей присоединения с фармацевтически приемлемой кислотой
EA201200498A1 (ru) Новый способ синтеза ивабрадина и его фармацевтически приемлемых кислотно-аддитивных солей
BR112012009292A2 (pt) processo para preparação do composto, sal de potássio, solvato de acetona, forma cristalina, e, composto
CO6710902A2 (es) Inhibidores de oxadiazol de la producción de leucotrienos
EA201200123A1 (ru) Новый способ синтеза ивабрадина и его фармацевтически приемлемых кислотно-аддитивных солей
MY164880A (en) Process for the preparation of isoxazolyl-methoxy-nicotinic acids
BR112012011786A2 (pt) "método para a produção de derivados de ácido glutâmico marcados por f-18"
EA201000397A1 (ru) Новый способ синтеза ивабрадина и его солей присоединения с фармацевтически приемлемой кислотой
EA201100230A1 (ru) Новый способ синтеза ивабрадина и его аддитивных солей с фармацевтически приемлемой кислотой
BR112012022356A2 (pt) processo para a preparação de 2-(ciclo-hexil-metil)-n-{2-[(2s)-1-metil-pirrolidin-2-il]etil)-1,2,3,4-tetra-hidroisoqunolina-7-suldonamida.
CY1116253T1 (el) Νεα μεθοδος συνθεσης του (2ε)-3-(3,4-διμεθοξυφαινυλ)προπ-2-ενονιτριλιου και εφαρμογη στη συνθεση της ιβαβραδινης και των αλατων προσθηκης αυτης με ενα φαρμακευτικως αποδεκτο οξυ
AR079128A1 (es) Procedimiento para preparar un polimorfo de la sal de colina de (4,6-bis( dimetilamino)2-(4-((4-(trifluorometil)-benzoil) amino) bencil) pirimidin-5-ilo
EA201201385A1 (ru) Новый способ синтеза ивабрадина и его фармацевтически приемлемых кислотно-аддитивных солей

Legal Events

Date Code Title Description
FB Suspension of granting procedure